Cellectis S.A. CMVLF

Company Overview

Cellectis S.A. is a French biotechnology company focused on developing gene-edited cell and gene therapies, primarily for oncology applications. The company operates in the biotechnology and life sciences industries and specializes in genome engineering using proprietary gene-editing technologies. Cellectis is best known for its work in allogeneic CAR-T cell therapies, which are designed as “off-the-shelf” treatments derived from healthy donors rather than a patient’s own cells. Its core technology platform is based on TALEN (Transcription Activator-Like Effector Nucleases) gene-editing technology, which the company uses to engineer immune cells for therapeutic applications.

The company’s primary revenue sources have included collaboration agreements, licensing arrangements, research partnerships, and milestone payments tied to development programs. Cellectis has historically partnered with major pharmaceutical and biotechnology firms to advance its pipeline and platform technologies. Founded in 1999 in France, the company evolved from an early-stage genome engineering research enterprise into a clinical-stage biotechnology company with operations spanning Europe and North America. Over time, it expanded its focus from broad gene-editing applications toward immuno-oncology and allogeneic cell therapy development.